Hong Kong Market Announcement Highlights: Seer Tech and Micot Pharma Debut Today, Cathay Pacific Reports 17% Passenger Growth in May

Stock News06-24

Key Corporate Developments:

SEER TECH (06106): Its Hong Kong public offering received 5,934.56 times subscription, with net proceeds from the global offering amounting to approximately HK$995.4 million.

MICOT PHARMA-B (02335): Its Hong Kong public offering was oversubscribed by 1,181.46 times, with the final offer price set at HK$18.2 per share.

An affiliate of ABBISKO-B (02256), Abbisko Pharmaceuticals, has deepened its research collaboration with Eli Lilly to jointly advance a novel candidate drug with global potential.

GUSHENGTANG (02273)'s subsidiary has acquired 100% equity in SANTE CLINICS and SANTE TCM, as well as 90% equity in Tianjin Bainian Renyitang.

AB&B BIO-TECH-B (02627): Its mRNA monkeypox vaccine has received an Investigational New Drug application approval from the Center for Drug Evaluation in China.

Operating Performance:

CATHAY PAC AIR (00293) reported a 17% year-on-year increase in passenger numbers for May, alongside an 11% rise in cargo volume.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177572709?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 09:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177572709","market":"sh","top_or_hot":-1,"title":"Hong Kong Market Announcement Highlights: Seer Tech and Micot Pharma Debut Today, Cathay Pacific Reports 17% Passenger Growth in May","media":"Stock News","content":"<p>Key Corporate Developments:<br><br><b>SEER TECH</b> (<b>06106</b>): Its Hong Kong public offering received 5,934.56 times subscription, with net proceeds from the global offering amounting to approximately HK$995.4 million.<br><br><b>MICOT PHARMA-B</b> (<b>02335</b>): Its Hong Kong public offering was oversubscribed by 1,181.46 times, with the final offer price set at HK$18.2 per share.<br><br>An affiliate of <b>ABBISKO-B</b> (<b>02256</b>), Abbisko Pharmaceuticals, has deepened its research collaboration with Eli Lilly to jointly advance a novel candidate drug with global potential.<br><br><b>GUSHENGTANG</b> (<b>02273</b>)'s subsidiary has acquired 100% equity in SANTE CLINICS and SANTE TCM, as well as 90% equity in Tianjin Bainian Renyitang.<br><br><b>AB&B BIO-TECH-B</b> (<b>02627</b>): Its mRNA monkeypox vaccine has received an Investigational New Drug application approval from the Center for Drug Evaluation in China.<br><br>Operating Performance:<br><br><b>CATHAY PAC AIR</b> (<b>00293</b>) reported a 17% year-on-year increase in passenger numbers for May, alongside an 11% rise in cargo volume.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Market Announcement Highlights: Seer Tech and Micot Pharma Debut Today, Cathay Pacific Reports 17% Passenger Growth in May</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Market Announcement Highlights: Seer Tech and Micot Pharma Debut Today, Cathay Pacific Reports 17% Passenger Growth in May\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-24 09:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Key Corporate Developments:<br><br><b>SEER TECH</b> (<b>06106</b>): Its Hong Kong public offering received 5,934.56 times subscription, with net proceeds from the global offering amounting to approximately HK$995.4 million.<br><br><b>MICOT PHARMA-B</b> (<b>02335</b>): Its Hong Kong public offering was oversubscribed by 1,181.46 times, with the final offer price set at HK$18.2 per share.<br><br>An affiliate of <b>ABBISKO-B</b> (<b>02256</b>), Abbisko Pharmaceuticals, has deepened its research collaboration with Eli Lilly to jointly advance a novel candidate drug with global potential.<br><br><b>GUSHENGTANG</b> (<b>02273</b>)'s subsidiary has acquired 100% equity in SANTE CLINICS and SANTE TCM, as well as 90% equity in Tianjin Bainian Renyitang.<br><br><b>AB&B BIO-TECH-B</b> (<b>02627</b>): Its mRNA monkeypox vaccine has received an Investigational New Drug application approval from the Center for Drug Evaluation in China.<br><br>Operating Performance:<br><br><b>CATHAY PAC AIR</b> (<b>00293</b>) reported a 17% year-on-year increase in passenger numbers for May, alongside an 11% rise in cargo volume.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1123","symbol_name":"航空公司","start_time":0,"source_url":"","article_id":"1177572709","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177572709","pubTimestamp":1782264026,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Key Corporate Developments:SEER TECH (06106): Its Hong Kong public offering received 5,934.56 times subscription, with net proceeds from the global offering amounting to approximately HK$995.4...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1123":"航空公司","VXUS":"国际股票ETF-Vanguard","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK4588":"碎股","02256":"和誉-B","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","BK1219":"保健护理服务","00293":"国泰航空","BK1161":"生物科技","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","02627":"中慧生物-B","02335":"麦科医药-B","BK4585":"ETF&股票定投概念","02273":"固生堂","IPOS":"Renaissance International IPO ETF","BK1561":"航空股","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","06106":"仙工智能","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC"},"translate_title":"香港市场公告集锦：Seer Tech和Micot Pharma今日亮相，国泰航空报告5月乘客增长17%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00293":1,"02627":1,"VXUS":1,"02256":1,"06106":1,"02273":1,"02335":1,"IPOS":1},"content_text":"Key Corporate Developments:SEER TECH (06106): Its Hong Kong public offering received 5,934.56 times subscription, with net proceeds from the global offering amounting to approximately HK$995.4 million.MICOT PHARMA-B (02335): Its Hong Kong public offering was oversubscribed by 1,181.46 times, with the final offer price set at HK$18.2 per share.An affiliate of ABBISKO-B (02256), Abbisko Pharmaceuticals, has deepened its research collaboration with Eli Lilly to jointly advance a novel candidate drug with global potential.GUSHENGTANG (02273)'s subsidiary has acquired 100% equity in SANTE CLINICS and SANTE TCM, as well as 90% equity in Tianjin Bainian Renyitang.AB&B BIO-TECH-B (02627): Its mRNA monkeypox vaccine has received an Investigational New Drug application approval from the Center for Drug Evaluation in China.Operating Performance:CATHAY PAC AIR (00293) reported a 17% year-on-year increase in passenger numbers for May, alongside an 11% rise in cargo volume.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177572709","isCrawlerRequest":true}